Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Treatment of Recurrent Clostridium difficile Diarrhea.

Huebner ES, Surawicz CM.

Gastroenterol Hepatol (N Y). 2006 Mar;2(3):203-208.

2.
3.

An observation on inappropriate probiotic subgroup classifications in the meta-analysis by Lau and Chamberlain.

McFarland LV.

Int J Gen Med. 2016 Sep 30;9:333-336. eCollection 2016. No abstract available.

4.

Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review.

McFarland LV.

Antibiotics (Basel). 2015 Apr 13;4(2):160-78. doi: 10.3390/antibiotics4020160. Review.

5.

Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis.

Lau CS, Chamberlain RS.

Int J Gen Med. 2016 Feb 22;9:27-37. doi: 10.2147/IJGM.S98280. eCollection 2016.

6.

New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics.

Patel R, DuPont HL.

Clin Infect Dis. 2015 May 15;60 Suppl 2:S108-21. doi: 10.1093/cid/civ177. Review.

7.

Probiotics for antibiotic-associated diarrhea: do we have a verdict?

Issa I, Moucari R.

World J Gastroenterol. 2014 Dec 21;20(47):17788-95. doi: 10.3748/wjg.v20.i47.17788. Review.

8.

Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells.

Boonma P, Spinler JK, Venable SF, Versalovic J, Tumwasorn S.

BMC Microbiol. 2014 Jul 2;14:177. doi: 10.1186/1471-2180-14-177.

9.

Survey and Systematic Literature Review of Probiotics Stocked in Academic Medical Centers within the United States.

Abe AM, Gregory PJ, Hein DJ, Cochrane ZR, Wilson AF.

Hosp Pharm. 2013 Nov;48(10):834-47. doi: 10.1310/hpj4810-834.

10.
11.

Development of microencapsulation delivery system for long-term preservation of probiotics as biotherapeutics agent.

Solanki HK, Pawar DD, Shah DA, Prajapati VD, Jani GK, Mulla AM, Thakar PM.

Biomed Res Int. 2013;2013:620719. doi: 10.1155/2013/620719. Epub 2013 Aug 21. Review.

12.

Efficacy of BIO K+ CL1285 in the reduction of antibiotic-associated diarrhea - a placebo controlled double-blind randomized, multi-center study.

Sampalis J, Psaradellis E, Rampakakis E.

Arch Med Sci. 2010 Mar 1;6(1):56-64. doi: 10.5114/aoms.2010.13508. Epub 2010 Mar 9.

13.

The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity.

Kang JK, Hwang JS, Nam HJ, Ahn KJ, Seok H, Kim SK, Yun EY, Pothoulakis C, Lamont JT, Kim H.

Antimicrob Agents Chemother. 2011 Oct;55(10):4850-7. doi: 10.1128/AAC.00177-11. Epub 2011 Aug 1.

14.

Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection.

Hickson M.

Therap Adv Gastroenterol. 2011 May;4(3):185-97. doi: 10.1177/1756283X11399115.

15.

Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science.

Petrof EO.

Antiinflamm Antiallergy Agents Med Chem. 2009 Sep 1;8(3):260-269.

16.

Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

McFarland LV.

World J Gastroenterol. 2010 May 14;16(18):2202-22. Review.

17.

Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review.

Tung JM, Dolovich LR, Lee CH.

Can J Gastroenterol. 2009 Dec;23(12):817-21. Review.

18.

Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation.

Thomas S, Przesdzing I, Metzke D, Schmitz J, Radbruch A, Baumgart DC.

Clin Exp Immunol. 2009 Apr;156(1):78-87. doi: 10.1111/j.1365-2249.2009.03878.x. Epub 2009 Jan 21.

19.

The human microbiome and probiotics: implications for pediatrics.

Hsieh MH, Versalovic J.

Curr Probl Pediatr Adolesc Health Care. 2008 Nov-Dec;38(10):309-27. doi: 10.1016/j.cppeds.2008.09.001. No abstract available.

20.

Supplemental Content

Support Center